(R)-N-ethyl-1-(1-naphthyl) ethylamine | 133469-32-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: (R)-N-ethyl-1-(1-naphthyl) ethylamine
• 英文别名: (R)-N-Ethyl-1-(naphthalen-1-yl)ethan-1-amine；(1R)-N-ethyl-1-naphthalen-1-ylethanamine
• CAS: 133469-32-6
• 化学式: C₁₄H₁₇N
• 分子量: 199.296
• InChiKey: WPUUEARORQAEAU-LLVKDONJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  (1R)-N-acetyl-(1-naphthyl)ethylamine 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 反应 28.0h， 以50%的产率得到(R)-N-ethyl-1-(1-naphthyl) ethylamine
  参考文献：
  名称：

  Duhamel, L.; Ravard, A.; Plaquevent, J. C., Bulletin de la Societe Chimique de France, 1990, # 6, p. 787 - 797

  摘要：

  DOI：

文献信息

• SUBSTITUTED ACETYLENIC COMPOUNDS USEFUL FOR THE TREATMENT OF DISEASES
  申请人：Liang Xifu

  公开号：US20100279936A1

  公开（公告）日：2010-11-04

  The invention relates to novel compounds according to formula Ia and Ib; (Formula Ia and Ib) wherein A represents substituted or unsubstituted C 1-10 heteroaryl, C 6-14 aryl or C 6-10 heterocycloalkylaryl; R 1 is C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 hydroxyalkyl, C 1-6 haloalkyl, C 1-6 amino, C 3-6 cycloalkyl, or C 1-6 heterocycloalkyl, each of which are optionally substituted; X represents —CR 3 R 4 —(CR 5 R 6 ) n —(CR 7 ═CR 8 ) m —(C 6-14 aryl) r -(C 1-10 heteroaryl) s -(CR 9 R 10 ) p —(CR 11 ═CR 12 ) q , R 2 represents C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 hydroxyalkyl, C 1-6 haloalkyl, C 1-6 amino, C 1-12 alkylsilyl, C 6-30 alkylarylsilyl, C 1-10 heteroaryl, C 6-14 aryl, C 1-10 heterocycloalkyl, C 1-10 heterocycloalkenyl, C 1-8 cycloalkyl, C 1-18 cycloalkenyl, each of which is optionally substituted, or R 2 represents hydrogen, carboxy, or hydroxy; or a pharmaceutically acceptable salt, solvate, or ester thereof; to processes for the preparation thereof, to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, wherein said compounds being useful, e.g. in the treatment of diseases associated with disturbances of CaSR activity, such as hyperparathyroidism.

  该发明涉及新型化合物，其符合公式Ia和Ib;（公式Ia和Ib）其中A代表取代或未取代的C1-10杂环芳基，C6-14芳基或C6-10杂环烷基芳基; R1为C1-6烷基，C2-6烯基，C2-6炔基，C1-6羟基烷基，C1-6卤代烷基，C1-6氨基，C3-6环烷基或C1-6杂环烷基，每个基团都可以取代; X代表—CR3R4—（CR5R6）n—（CR7═CR8）m—（C6-14芳基）r-（C1-10杂环芳基）s-（CR9R10）p—（CR11═CR12）q，R2代表C1-6烷基，C2-6烯基，C2-6炔基，C1-6羟基烷基，C1-6卤代烷基，C1-6氨基，C1-12烷基硅烷基，C6-30烷基芳基硅烷基，C1-10杂环芳基，C6-14芳基，C1-10杂环烷基，C1-10杂环烯基，C1-8环烷基，C1-18环烯基，每个基团都可以取代，或R2代表氢，羧基或羟基;或其药学上可接受的盐，溶剂或酯;用于制备该化合物的工艺，以及用于治疗的化合物，包括该化合物的制药组合物，其中该化合物可用于治疗与CaSR活性紊乱有关的疾病，例如甲状旁腺功能亢进症。
• DUHAMEL, L.;RAVARD, A.;PLAQUEVENT, J. C.;PLE, G.;DAVOUS, D., BULL. SOC. CHIM. FR. ,(1990) N, C. 787-797
  作者：DUHAMEL, L.、RAVARD, A.、PLAQUEVENT, J. C.、PLE, G.、DAVOUS, D.

  DOI：——

  日期：——
• SUBSTITUTED CHROMAN COMPOUNDS AS CALCIUM SENSING RECEPTOR MODULATORS
  申请人：Lupin Limited

  公开号：EP2817299B1

  公开（公告）日：2019-06-12
• Biarylurea derivatives
  申请人：Hayama Takashi

  公开号：US20070027147A1

  公开（公告）日：2007-02-01

  The present invention relates to a compound of Formula (I) and the manufacturing method(s) thereof and the use thereof: Formula (I) wherein: Ar is a nitrogen-containing heteroaromatic ring group; X and Z are each a carbon atom, and so on; Y is CO, and so on; R 1 is a hydrogen atom, and so on; R 2 and R 3 are each a hydrogen atom, and so on; R 4 and R 5 are each a hydrogen atom, and so on; and the formula is a single bond or a double bond. According to the present invention, the compound of the present invention can provide Cdk4 and/or Cdk6 inhibitors for treating malignant tumors, because the compounds of the present invention exhibit a prominent growth inhibitory activity against tumor cells.
• US7354946B2
  申请人：——

  公开号：US7354946B2

  公开（公告）日：2008-04-08